Luminopia, Inc., a commercial-stage company pioneering a new class of treatments for neuro-visual disorders, today announced that the company’s lead product, Luminopia, was named one of TIME’s Best Inventions of 2023.
Luminopia is the first FDA-approved1 digital therapeutic for a neuro-visual disorder, indicated to improve vision in children, aged 4-7, with amblyopia (lazy eye). Amblyopia is the leading cause of vision loss in children, affecting 3% of children worldwide. Traditional treatments include glasses, eye-patches, and blurring (atropine) eye drops, but these options leave a significant unmet need due to poor compliance, residual vision loss, and negative psychosocial impacts.
Read More: https://www.businesswire.com/news/home/20231024543829/en/Luminopia-Named-to-TIME%E2%80%99s-List-of-the-Best-Inventions-of-2023